How do you define PIK3CA/AKT/PTEN alteration for capivasertib use?

Patient with stage IV ER+PR+Her2- breast cancer progressed after CDK4/6 inhibitor+AI and then on Elacestrant. Guardant 360 showed ESR1 mutation and PIK3CA amplification. Does PIK3CA amplification qualify for the definition of PIK3CA/AKT/PTEN alteration for use of capivasertib?

Community PollStarted

Which alterations from the PIK3CA/AKT/PTEN pathway would you potentially target with capivasertib in patients with metastatic HR+Her2- breast cancer?

61 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers

Mednet MemberInvited Expert

Medical Oncology · Duke University

Answered on

For CAPItello-291, tumors had to have activating mutations in PIK3CA or AKT or inactivating alterations in PTEN genes – i.e., genes that were altered/not normal. Gene amplification refers to an increase in the number of copies of the same, normal gene, not an increased rate of transcription. So, PIK...

Join for free or sign in to see the full answer

Mednet Member

Medical Oncology · Cleveland Clinic

Answered on

Currently, I am only considering activating mutations in PIK3CA/AKT as well as PTEN alterations for capivasertib use. These are the types of changes that were considered “eligible” in CAPItello-291 for the “pathway altered” analysis. That being said, there was a signal of benefit in the non-pathway ...

Join for free or sign in to see the full answer